Lysine Per Se Or Salt Thereof Patents (Class 562/562)
-
Patent number: 11505519Abstract: Methods for syntheses of organic acids from ?-keto acids, including methods for syntheses of isotopically enriched organic acids from ?-keto acids are disclosed. The isotopically enriched organic acids are useful, for example, in metabolic flux analyses.Type: GrantFiled: January 17, 2020Date of Patent: November 22, 2022Assignee: Furman UniversityInventors: Gregory Gardner Springsteen, Robert Trent Stubbs
-
Patent number: 9376364Abstract: The invention provides a method for preparing a succinic acid, which method includes the steps of: providing magnesium succinate; acidifying the magnesium succinate with hydrochloric acid (HCl), thereby obtaining a solution including succinic acid and magnesium chloride (MgCl2); optionally a concentration step, wherein the solution including succinic acid and MgCl2 is concentrated; precipitating succinic acid from the solution including succinic acid and MgCl2, thereby obtaining a succinic acid precipitate and a MgCl2 solution. The addition of HCl to a magnesium salt of succinic acid and subsequent precipitation of succinic acid from the solution leads to a very efficient separation of succinic acid from a magnesium succinate solution.Type: GrantFiled: August 16, 2012Date of Patent: June 28, 2016Assignee: PURAC BIOCHEM B.V.Inventors: André Banier De Haan, Jan Van Breugel, Paulus Loduvicus Johannes Van Der Weide, Peter Paul Jansen, José María Vidal Lancis, Agustín Cerdà Baró
-
Publication number: 20150053211Abstract: An aqueous oral spray designed to treat mouth guards against bacterial infection comprising: 1. A naturally derived di-basic amino acid derivative, 2. A natural sweetener which inhibits the adhesion of bacteria to the oral cavity and, 3. Optionally a natural flavor and/or natural dye 4. Optionally a mouth guard surface modified to absorb specific components of above oral aqueous solution so as to render mouth guard more effective overtime in inhibiting microorganism growth on surface and in contact with mouth surfaces compared with unmodified mouth guard surface.Type: ApplicationFiled: August 26, 2013Publication date: February 26, 2015Inventors: Richard F. Stockel, Dennis R. Hanlon, Bruce Alan Nascimbeni, John Edward McCaskie
-
Publication number: 20140350128Abstract: Provided is a compound capable of gelling various aqueous compositions containing salt, acid and the like. A basic amino acid derivative represented by the formula (1): wherein each substituent is as defined in DESCRIPTION, or a salt thereof.Type: ApplicationFiled: August 6, 2014Publication date: November 27, 2014Applicant: AJINOMOTO CO., INC.Inventors: Kenji HANABUSA, Masahiro SUZUKI, Takanori SUGIMOTO
-
Publication number: 20140314850Abstract: The present application relates to functionalized nanodiamonds, to complexes comprising a functionalized nanodiamond reversibly bound to a nucleic acid and to compositions comprising such functionalized nanodiamonds and complexes. In particular, the functionalized nanodiamonds comprise at least one naturally occurring basic amino acid, or analogs or derivatives thereof, covalently linked to a nanodiamond. The present application also includes methods and uses of the complexes and compositions, for example for delivering a nucleic acid to a cell.Type: ApplicationFiled: April 17, 2014Publication date: October 23, 2014Applicant: University of SaskatchewanInventors: Ildiko Badea, Ronald Verrall, Jackson M. Chitanda, Randeep Kaur, Saniya Alwani
-
Publication number: 20140243282Abstract: The present invention relates to novel drug conjugates, where in two drugs are linked together through an appropriate linker having at least two functional groups capable of forming covalent bond with drugs D1 and D2. The invention also relates to developing novel compositions, methods for their preparation and their use in treating various disease conditions.Type: ApplicationFiled: December 12, 2011Publication date: August 28, 2014Inventor: Satish Reddy Kallam
-
Patent number: 8779191Abstract: The invention provides methods and compositions for preparing lisdexamfetamine and salts thereof. More particularly, the invention provides, for example, methods of preparing lisdexamfetamine from D-amphetamine.Type: GrantFiled: December 20, 2010Date of Patent: July 15, 2014Assignee: Cambrex Charles City, Inc.Inventors: Michael J. Bauer, Gary Richard Callen, Judi Christine Humphrey, Todd Jeffrey Johnson, Matthew Wendell Schiesher
-
Publication number: 20140099696Abstract: Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions.Type: ApplicationFiled: April 30, 2013Publication date: April 10, 2014Applicant: Ansun Biopharma, Inc.Inventors: Michael P. Malakhov, Fang Fang
-
Patent number: 8653136Abstract: Compositions based on amino acids are described, for improving the myocardial ventricular function in patients suffering from diabetes, particularly but not exclusively II type diabetes. The compositions according to the invention comprise up to 75% of the branched chain amino acids leucine, isoleucine and valine, as active ingredients. Preferably, the compositions also comprise, as further active ingredients, up to 50% of threonine and lysine. Other essential amino acids are preferably also provided, in particular methionine, phenylalanine, histidine, tryphtophan, as well as non essential amino acids, in particular tyrosine and/or cyst(e)ine (i.e., cystine and cysteine). Other amino acids can be added, provided that their sum is in a percentage being lower than 20% with respect to the other active ingredients, and less than 10% for each single amino acid.Type: GrantFiled: April 17, 2008Date of Patent: February 18, 2014Assignee: Determinants of Metabolism Research Laboratory S.R.L.Inventors: Franco Conti, Francesco Saverio Dioguardi
-
Patent number: 8609160Abstract: A method of treating a patient infected with a lipid encapsulated virus by administering to the patient about 1000 mg to about 5000 mg per day of a nutritional supplement having from about 40 to about 80 wt. % L-lysine, from about 20 to about 50 wt. % butylated hydroxytoluene and from about 1 to about 10 wt. % Echinacea. Administration of the nutritional supplement inhibits ulcer formation resulting from lipid encapsulated virus infections such as herpes simplex I and II infections.Type: GrantFiled: May 21, 2012Date of Patent: December 17, 2013Inventor: Dominick Golio
-
Patent number: 8557869Abstract: This invention provides diets useful for promoting fat loss in animals having a total lysine to metabolizable energy ratio of from about 6 to about 10 g/Mcal. This invention also provides compositions for promoting fat loss in animals, methods for preparing the compositions, methods for using the diets and compositions, articles of manufacture comprising the diets and compositions, and means for communicating information or instructions about such diets, compositions, methods, and articles of manufacture.Type: GrantFiled: August 5, 2009Date of Patent: October 15, 2013Assignee: Hill's Pet Nutrition, Inc.Inventors: Ryan Michael Yamka, Kim Gene Friesen
-
Publication number: 20130256228Abstract: This disclosure describes draw solution compositions for FO processes which increase the available membrane area for permeation and are also amenable to reconcentration with standard techniques, such as membrane filtration and evaporative technologies. The composition are comprised of a water soluble draw solute having surface active properties, i.e., a surfactant.Type: ApplicationFiled: March 14, 2013Publication date: October 3, 2013Inventors: Upen J. Bharwada, Isaac V. Farr
-
Patent number: 8470781Abstract: The present invention provides novel physiological substrates of mammalian glutaminyl cyclase (QC, EC 2.3.2.5), new effectors of QC and the use of such effectors and pharmaceutical compositions comprising such effectors for the treatment of diseases that can be treated by modulation of QC-activity, e.g. diseases selected from the group consisting of duodenal cancer with or w/o Heliobacter pylori infections, colorectal cancer, Zolliger-Ellison syndrome, Familial British Dementia and Familial Danish Dementia.Type: GrantFiled: July 29, 2008Date of Patent: June 25, 2013Assignee: Probiodrug AGInventors: Stephan Schilling, Torsten Hoffmann, Andre Johannes Niestroj, Hans-Ulrich Demuth, Ulrich Heiser
-
Publication number: 20130136832Abstract: This invention discloses a method of preservation of a food product comprising the step of adding 1) a first component comprising between 10 ppm and 1% of a biocidal salt of N?—(C1-C22) alkanoyl di-basic amino acid alkyl (C1-C22) ester cationic biocidal molecule with an anionic counterion, and 2) a second component comprising from 10 ppm to 1% by weight an acyl monoglyceride, directly to a food product. The preferred cationic biocidal molecule comprises N?-lauroyl-L-arginine ethyl ester (“LAE”). The invention also discloses the method of preservation of a food product using salts of a N?—(C1-C22) alkanoyl di-basic amino acid alkyl (C1-C22) ester cationic biocidal molecule and an anionic counterion with or without a monoglyceride of a fatty acid, whereby the packaging film is compounded with the salts and the optional monoglyceride of a fatty acid.Type: ApplicationFiled: April 4, 2011Publication date: May 30, 2013Inventors: Anthony Joseph Sawyer, Richard F. Stockel
-
Publication number: 20130071439Abstract: Methods of treating or reducing biofilms, treating a biofilm-related disorder, and preventing biofilm formation using D-amino acids are described.Type: ApplicationFiled: January 10, 2011Publication date: March 21, 2013Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Richard Losick, Jon Clardy, Roberto Kolter, Illana Kolodkin-Gal, Diego Romero, Shugeng Cao
-
Publication number: 20130046017Abstract: The invention relates to the use of compounds of general formula (I): CH3(—CH?CH)3—R??(I) wherein R is selected from CO—O—R? or CO—O(?), R? being selected from H, alkyl or alkenyl from C1 to C22, or sugars, and their pharmaceutically acceptable salts, preferably such as sodium, potassium, or lysine salts, each compound of general formula (I) being used as such or mixed with one or more of the others, as active ingredients in a pharmaceutical or cosmetic composition provided with antioxidant activity against free radicals.Type: ApplicationFiled: April 22, 2011Publication date: February 21, 2013Applicant: GIULIANI S.P.A.Inventors: Giammaria Giuliani, Anna Benedusi
-
Patent number: 8367121Abstract: This invention describes a comprehensive nutraceutical designed to antagonize major mitigating factors to the degenerative process associated with Parkinson's disease. The formulation is comprised of a primary base of pyruvate, succinate, ?-Ketoglutarate and/or oxaloacetate, niacin/NADH, fruit extracts, anthocyanins, further combined with specific macro/micronutrients, trace elements, amino acids, flavonoids and concentrated plant sources. The nutraceutical contains all natural substances that should mitigate many of the neurodegenerative processes known to be associated with PD. Mechanisms addressed are to prevent the loss of ATP/by 1-methyl-4-phenylpyridinium rotenone, scavenge hydrogen peroxide/O2.Type: GrantFiled: February 6, 2010Date of Patent: February 5, 2013Assignee: Florida A & M UniversityInventors: Elizabeth Anne Mazzio, Karam F Soliman
-
Publication number: 20120329846Abstract: Disclosed is an agent for use in the treatment or prevention of inflammatory bowel disease. Also disclosed is an agent for inhibiting the production of TNF-?. A therapeutic or prophylactic agent for inflammatory bowel disease comprising at least one amino acid selected from the group consisting of lysine, histidine, phenylalanine, methionine, tryptophan, glutamine, glycine, cysteine, cystine and threonine, the amino acid being administered at a dose of 0.1 to 4000 mg/kg per day; and a TNF-? production inhibitor comprising an amino acid selected from the group consisting of histidine, phenylalanine and tryptophan, the amino acid being administered at a dose of 0.1 to 4000 mg/kg per day.Type: ApplicationFiled: March 27, 2012Publication date: December 27, 2012Applicant: Ajinomoto Co., Inc.Inventors: Hideki Matsumoto, Tomohisa Okutsu, Tomoko Takeda, Hideki Suzuki, Tetsuo Yano, Masaki Hashimoto, Miho Ono, Manabu Suzuki
-
Patent number: 8334403Abstract: Compounds and methods for double-stranded DNA cleavage of light-activated lysine conjugates are enhanced at the slightly acidic pH suitable for selective targeting of cancer cells by the presence of two amino groups of different basicities. The first amino group plays an auxiliary role enhancing solubility and affinity to DNA whereas the second amino group which is positioned next to the light-activated DNA-cleaver undergoes protonation at the desired pH threshold. Protonation results in two synergetic effects which account for the increased DNA-cleaving ability at the lower pH: tighter binding to DNA at the lower pH; and the unproductive pathway which quenches the excited state of the photocleaver through intramolecular electron transfer is eliminated once the donor amino group next to the chromophore is protonated. The utility of these molecules for phototherapy of cancer is confirmed by the drastic increase in toxicity of five conjugates against cancer cell lines upon photoactivation.Type: GrantFiled: December 17, 2009Date of Patent: December 18, 2012Assignee: Florida State University Research Foundation, Inc.Inventors: Igor Alabugin, Serguei Kovalenko, Wang Yong Yang, Kerry Gilmore, Boris Breiner
-
Patent number: 8247006Abstract: A method of treating a patient infected with a lipid encapsulated virus by administering to the patient about 1000 mg to about 5000 mg per day of a nutritional supplement having from about 40 to about 80 wt. % L-lysine, from about 20 to about 50 wt. % butylated hydroxytoluene and from about 1 to about 10 wt. % Echinacea. Administration of the nutritional supplement inhibits ulcer formation resulting from lipid encapsulated virus infections such as herpes simplex I and II infections.Type: GrantFiled: June 22, 2010Date of Patent: August 21, 2012Inventor: Dominick I. Golio
-
Patent number: 8242307Abstract: A process of forming a double strand cleavage in DNA includes providing a reaction mixture containing double stranded DNA having a break in a first strand defining a target site in a second strand. The method continues by adding to the reaction mixture a photoreactive lysine conjugate selected from a lysine-enediyne conjugate, a lysine-acetylene conjugate or a combination thereof, for a time sufficient for the lysine conjugate to bind to the DNA adjacent the target site. The reaction mixture is then irradiated with electromagnetic radiation sufficient to photoactivate the lysine conjugate to cleave the second strand adjacent the target site.Type: GrantFiled: December 10, 2009Date of Patent: August 14, 2012Assignee: Florida State University Research Foundation, Inc.Inventors: Igor V. Alabugin, Boris Breiner, Joerg C. Schlatterer, Serguei V. Kovalenko, Nancy L. Greenbaum
-
Coenzyme Q10 Nanoparticles, Preparation Method Thereof and Composition Containing Said Nanoparticles
Publication number: 20120041178Abstract: Provided are a coenzyme Q10 nanoparticle, a method of preparing the same and a composition having the nanoparticle. According to the present invention, Coenzyme Q10 may be dissolved in only a water-miscible organic solvent, and easily made into a nano-sized particle and solubilized under a low energy condition, for example, by simple stirring. The coenzyme Q10 may be dispersion-stabilized by an amino acid or protein. The coenzyme Q10 is formed in a nano-sized particle and solubilized, an absorption rate may be increased and simultaneously deliver the amino acid and protein with the nanoparticle. Thus, the coenzyme Q10 nanoparticle can be effectively used in food, cosmetics and medicine.Type: ApplicationFiled: April 6, 2010Publication date: February 16, 2012Applicant: Korea Research Institute of Bioscience and BiotechnologyInventors: Bong Hyun Chung, Jung Hyun Han -
Publication number: 20110166379Abstract: The invention provides a method of synthesis of N-6-trimethyl-L-lysine (TML) derivative compounds for potential treatment of disorders resulting from deficiencies in the TML-carnitine pathway. The invention also provides a method of purification of TML and TML derivative compounds. The treatment of conditions of the diseases late infantile neuronal ceroid lipofuscinosis (LINCL) and neuronal ceroid lipofuscinosis (NCL) with TML were shown in the original parent application.Type: ApplicationFiled: March 9, 2011Publication date: July 7, 2011Inventors: Suresh C. Srivastava, Sant K. Srivastav, Stanley J. Szymanski, JR.
-
Publication number: 20110144037Abstract: The presently disclosed and claimed inventive concepts include inhibitors of antiplasmin cleaving enzyme (APCE) and fibroblast activation protein alpha (FAP) which can be used in various therapies related to disorders of fibrin and ?2-antiplasmin and abnormal cell proliferation. The presently disclosed and claimed inventive concepts also include substrates of APCE and FAP, which may be used, for example, in screening methods for identifying such inhibitors. The presently disclosed and claimed inventive concepts further include, but are not limited to, methods of treating or inhibiting atherosclerosis and thrombus disorders by altering the ratios of types of plasma ?2-antiplasmin and to methods of treating conditions involving abnormal cell proliferation such as cancers.Type: ApplicationFiled: December 15, 2010Publication date: June 16, 2011Inventors: Patrick A. McKee, Kenneth W. Jackson, Kyung N. Lee, Victoria J. Christiansen
-
Publication number: 20110136726Abstract: A novel class of antimicrobial polymeric agents which are designed to exert antimicrobial activity while being stable, non-toxic and avoiding development of resistance thereto and a process of preparing same are disclosed. Further disclosed are pharmaceutical compositions containing same and a method of treating medical conditions associated with pathological microorganisms, a medical device, an imaging probe and a food preservative utilizing same. Further disclosed are conjugates of an amino acid residue and a hydrophobic moiety residue and a process of preparing same.Type: ApplicationFiled: February 21, 2011Publication date: June 9, 2011Applicant: Technion Research & Development Foundation Ltd.Inventors: Amram MOR, Inna Radzishevsky
-
Publication number: 20110044974Abstract: The object of the present invention is analogues of peptides or parent proteins, these peptide analogues, comprising at least one aza-?3 aminoacyl residue, and also their uses in pharmaceutical compositions or for the diagnosis of pathologies wherein the aforesaid peptides or parent proteins are involved.Type: ApplicationFiled: June 11, 2004Publication date: February 24, 2011Inventors: Michele Baudy Floc'h, Olivier Busnel, Sylviane Muller
-
Patent number: 7862838Abstract: A composition and regimen for the treatment of herpes simplex and herpes zoster, primarily through elimination of the pathogenetic conditions by taking into account both pathogenesis and etiology thereof are disclosed. Administration of 1) repeated large dosages of vitamin B2 to eliminate severe vitamin B2 deficiency inherent in herpes simplex and herpes zoster; 2) Strobilanthes cusia and Berberine to ameliorate febrile illness and to clear “hot” condition; 3) Zizyphus semen to relieve psychological stress; and 4) L-lysine to antagonize arginine and alleviate anxiety-all these hereof are for eliminating the pathogenetic conditions. These, in combination with antiviral agents if necessary, constitute the scope and the spirit of the present invention.Type: GrantFiled: August 31, 2009Date of Patent: January 4, 2011Inventor: Qing Si Zeng
-
Publication number: 20100184054Abstract: A process for the selective binding of an aggregating abnormal form of a protein in the presence of the nonaggregating normal form of the protein, including contacting under selective binding conditions a material containing both the abnormal and normal forms with a binding agent which is a polyionic material having a binding avidity for the aggregating form of the protein as present in the sample.Type: ApplicationFiled: December 22, 2009Publication date: July 22, 2010Applicant: MICROSENS BIOPHAGE LIMITEDInventors: Amin R. Lane, Christopher J. Stanley, Stuart M. Wilson
-
Publication number: 20100160248Abstract: A nutrient composition comprises an essential nutrient in which at least one exchangeable H atom is 2H and/or at least one C atom is 13C. The nutrient is thus protected from, inter alia, reactive oxygen species.Type: ApplicationFiled: March 8, 2007Publication date: June 24, 2010Inventor: Mikhail Sergeevich Shchepinov
-
Publication number: 20100130432Abstract: This invention relates to non-natural desamino amino acid compounds, methods of making, and peptides containing these compounds as their N-terminus moieties. A preferred example is neurotensin (8-13) in which the N terminus is an alpha desamino N,N dimethyl homolysine residue.Type: ApplicationFiled: December 15, 2006Publication date: May 27, 2010Inventors: Justin O. Brower, Thomas A. Dix
-
Publication number: 20100095749Abstract: The present invention provides a technique for crystallizing a desired protein at a high probability; namely, a protein crystallizing agent and a method of crystallizing protein. The present invention also provides a technique for determining the conditions for protein crystallization easily with high efficiency; namely, a method of screening the conditions for protein crystallization and a protein crystallization screening reagent. As the protein crystallizing agent, at least one compound selected from the group consisting of a basic amino acid, acidic amino acid, ester derivative of amino acid and amide derivative of amino acid is used, or at least one of these compounds is used in combination with another protein crystallizing agent.Type: ApplicationFiled: September 19, 2007Publication date: April 22, 2010Inventors: Hiroshi Yamaguchi, Len Ito
-
Publication number: 20100035991Abstract: The present invention provides amine base salts of SAHA, polymorphs and pharmaceutical compositions thereof. The invention provides a method of treating cancer by administering the pharmaceutical composition. The invention also provides a crystalline composition comprising the amine base and SAHA. The invention also provides methods of obtaining the amine base salt and crystalline composition.Type: ApplicationFiled: September 24, 2007Publication date: February 11, 2010Inventors: Arlene McKeown, Fuh-Rong Tsay
-
Publication number: 20100029768Abstract: This invention provides diets useful for promoting fat loss in animals having a total lysine to metabolizable energy ratio of from about 6 to about 10 g/Mcal. This invention also provides compositions for promoting fat loss in animals, methods for preparing the compositions, methods for using the diets and compositions, articles of manufacture comprising the diets and compositions, and means for communicating information or instructions about such diets, compositions, methods, and articles of manufacture.Type: ApplicationFiled: August 5, 2009Publication date: February 4, 2010Applicant: Hill's Pet Nutrition, Inc.Inventors: Ryan Michael Yamka, Kim Gene Friesen
-
Publication number: 20090281347Abstract: To provide a production method of phosphates of amino acids, typified by ?-aminolevulinic acid phosphate, or esters thereof. A method for producing phosphates of an amino acid or an ester thereof, which comprises allowing an amino acid, an ester thereof or a salt thereof to coexist with phosphoric acids and a basic nitrogen-containing compound.Type: ApplicationFiled: March 1, 2007Publication date: November 12, 2009Applicant: COSMO OIL CO., LTD.Inventor: Naohisa Tachiya
-
Publication number: 20090214535Abstract: The present inventor discovered stabilizing agents/stabilizing conditions for suppressing isomerization reactions of sc(Fv)2. It was also discovered that the above-mentioned isomerization reactions can be suppressed through use of freeze-dried formulations. As disclosed herein, by applying the discovered stabilizing agents/stabilizing conditions or the freeze-dried formulation, the isomerization reaction of an sc(Fv)2-type molecule from the bivalent scFv type to the single chain diabody type, and/or the isomerization reaction from a single chain diabody type to a bivalent scFv type can be suppressed in both directions or one direction.Type: ApplicationFiled: June 9, 2006Publication date: August 27, 2009Applicant: Chugai Seiyaku Kabushiki KaishaInventor: Tomoyuki Igawa
-
Patent number: 7572462Abstract: The invention provides a nutritional supplement system and program for patients undergoing or who have undergone a surgical or other invasive or stressful procedure, or who have suffered an injury. This nutritional supplement for the peri-operative period is designed to prevent deficiencies of nutrients needed for optimal health and healing during this period or for general application and to enable the person receiving the nutritional supplementation to achieve maximum healing and rapid recovery from a procedure or injury.Type: GrantFiled: March 19, 2007Date of Patent: August 11, 2009Inventor: Edward M. Lane
-
Publication number: 20090131337Abstract: The present invention provides a hair growth agent having novel action mechanism and a hair growth composition containing the agent. Specifically, the present invention provides a novel hair growth composition containing one or more kinds of epsilon-N-(gamma-glutamyl)lysine or a salt thereof.Type: ApplicationFiled: December 8, 2008Publication date: May 21, 2009Applicant: AJINOMOTO CO. INCInventors: Maki SHIMADA, Yoshinobu TAKINO
-
Publication number: 20090131526Abstract: The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.Type: ApplicationFiled: August 29, 2008Publication date: May 21, 2009Applicant: SHIRE LLCInventors: Travis Mickle, Suma Krishnan, Barney Bishop, Christopher Lauderback, James Scott Moncrief, Robert Oberlender, Thomas Piccariello, Bernhard J. Paul, Christopher A. Verbicky
-
Publication number: 20090105328Abstract: An Amino Acid Compound is described. The Amino Acid Compound may comprise an Amino Acid and one of a Nitrate and a Nitrite. The Amino Acid may be one of Aspartic Acid, Cysteine, Glycine, Lysine, Methionine, Proline, Tyrosine, and Phenylalanine.Type: ApplicationFiled: December 17, 2008Publication date: April 23, 2009Inventors: Ronald Kramer, Alexander Nikolaidis
-
Publication number: 20080188399Abstract: Monodisperse macromolecular conjugate compositions of a peptidic carrier irreversibly or reversibly conjugated with one or more effectors and one or more therapeutic agents, wherein at least one effector or therapeutic agent is attached to a pendant reactive group on said peptidic carrier via a water-soluble polymer. Monodispersity is obtained through the use of orthogonal and separate conjugation reactions.Type: ApplicationFiled: February 16, 2006Publication date: August 7, 2008Applicant: Ruthers, The State University of New JerseyInventors: Patrick J. Sinko, Stanley Stein, Simi Gunaseelan, Shahriar Pooyan, Li Wan, Xiaoping Zhang
-
Patent number: 7205007Abstract: The invention provides a nutritional supplement system and program for patients undergoing or who have undergone a surgical or other invasive or stressful procedure, or who have suffered an injury. This nutritional supplement for the peri-operative period is designed to prevent deficiencies of nutrients needed for optimal health and healing during this period or for general application and to enable the person receiving the nutritional supplementation to achieve maximum healing and rapid recovery from a procedure or injury.Type: GrantFiled: October 4, 2005Date of Patent: April 17, 2007Assignee: Fairfield Clinical Trials, LLCInventor: Edward M. Lane
-
Patent number: 7163810Abstract: In a method for producing a target substance by using a microorganism comprising culturing a microorganism having an ability to produce the target substance in a medium to produce and accumulate the target substance in the medium or cells of the microorganism and collecting the target substance from the medium or the cells of the microorganism, there are used, as the microorganism, a microorganism to which a methanol dehydrogenase gene is introduced, of which activities of hexulose phosphate synthase and phosphohexuloisomerase are enhanced and which is modified so that an ability to utilize methanol should be imparted or enhanced, and there is used a medium containing methanol as a carbon source.Type: GrantFiled: September 5, 2002Date of Patent: January 16, 2007Assignee: Ajinomoto Co., Inc.Inventors: Hisashi Yasueda, Ryo Takeshita
-
Patent number: 7161029Abstract: A diL-lysine monosulfate trihydrate crystal which has a large tabular form and is more easily separable from the mother liquor. The crystal is obtained by a novel process of conducting crystallization at a lower temperature.Type: GrantFiled: December 17, 2003Date of Patent: January 9, 2007Assignee: Ajinomoto Co., Inc.Inventors: Takeshi Kushiku, Dave Steckelberg, Toshiya Tanabe, Jirou Haga
-
Patent number: 7125872Abstract: There are disclosed ?-sheet mimetics and methods relating to the same for imparting or stabilizing the ?-sheet structure of a peptide, protein or molecule. In one aspect, ?-sheet mimetics are disclosed having utility as protease inhibitors in general and, more specifically, as serine protease inhibitors such as thrombin, elastase and Factor X inhibitors. In one embodiment, the ?-sheet mimetic is a thrombin inhibitor.Type: GrantFiled: December 22, 2003Date of Patent: October 24, 2006Assignee: Myriad Genetics, Inc.Inventors: Michael Kahn, Cyprian O. Ogbu, Masakatsu Eguchi, Hwa-Ok Kim, Patrick Douglas Boatman, Jr.
-
Patent number: 7026297Abstract: Compounds of formula (I) wherein: Q represents an amidino group, a cyano group or a group of formula XYN—, (where X and Y are hydrogen or various groups); Ra represents alkylene; Rb and Rc each represents alkylene, the total number of carbon atoms in said straight chains of Rb and Rc being 7); R2 and R3 each represents hydrogen, or a group of formula R, RCO—, ROCO—, or RNHCO—, where R represents alkyl or aryl; the chiral carbon atom indicated by the asterisk is in the L configuration; Z is an aromatic amino acid residue; n is 0 or 1; R1 represents hydrogen, alkyl or aryl; and W represents hydrogen, alkyl or aryl; and pharmaceutically acceptable salts thereof have the ability to protect against the neuronal damage which may be caused by an ischemic event.Type: GrantFiled: November 20, 2003Date of Patent: April 11, 2006Assignee: University of SouthamptonInventors: Lars Eric Sundstrom, Fausto Iannotti, Mark Bradley, Ashley Ker Pringle
-
Patent number: 6992067Abstract: Compounds of the formula I, in which R1, R2, R3, R4, R5, and R6 have the meanings given in the description, and their physiologically acceptable salts. The compounds are suitable for use, for example, as hypolipidemics.Type: GrantFiled: December 19, 2001Date of Patent: January 31, 2006Assignee: Aventis Pharma Deutschland GmbHInventors: Heiner Glombik, Werner Krame, Stefanie Flohr, Wendelin Frick, Hubert Heuer, Gerhard Jaehne, Andreas Lindenschmidt, Hans-Ludwig Schäfer
-
Patent number: 6911470Abstract: Polyoxometalate compounds which exhibit anti-retroviral activity are disclosed. Compounds with anti-retroviral activity include those having the following general molecular formulas: M7PW11O39 M8SiW11O39 M9HSiW9O34 M8HPW9O34 M10(TM)4(PW9O34)2 M16(TM)4(P2W15O56)2 M14[NaP5W30O110] M12(TM)3(PW9O34)2 M6P2W18O62 wherein M is an alkali metal, NH4+ or other common monocation or soluble dication, or any combination of the above provided adequate water solubility is exhibited, or histidinium ion, argininium ion, or lysinium ion or any dication of a dipeptide or oligopeptide with 2 protonated basic amino acid residues, or any combination of these monocations or dications with each other or with any common inorganic cation, and TM is a divalent transition metal ion, such as Mn, Fe, Co, Ni, Cu and Zn.Type: GrantFiled: October 25, 1993Date of Patent: June 28, 2005Inventors: Raymond F. Schinazi, Craig L. Hill
-
Patent number: 6893848Abstract: The present invention relates to a novel aspartokinase derived from a Coryneform bacterium; a DNA encoding the enzyme; a recombinant DNA containing the above DNA; a Coryneform bacterium having the above recombinant DNA or a Coryneform bacterium having the DNA on its chromosome; and a process for producing L-lysine by culturing the above microorganism. Construction has been successfully made of a DNA encoding an aspartokinase freed from concerted feedback inhibition by L-lysine and L-threonine derived from a Corynebacterium and has a nucleotide sequence encoding an amino acid sequence wherein the amino acid residue at position 311 is an amino acid other than Thr in the amino acid sequence shown by SEQ ID NO: 18.Type: GrantFiled: April 14, 2000Date of Patent: May 17, 2005Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Haruhiko Yokoi, Junko Ohnishi, Keiko Ochiai, Yoshiyuki Yonetani, Akio Ozaki
-
Publication number: 20040214895Abstract: Herein is disclosed an aqueous stable lysine solution containing an acid radical in such amount that the solubility of lysine therein has been increased than in the corresponding aqueous lysine base solution, whereby during storage of lysine in the form of a free-lysine solution (liquid composition), the precipitation of lysine base crystals due to the drop in temperature is prevented thereby improving the handling thereof during transportation (transfer) etc.Type: ApplicationFiled: May 21, 2004Publication date: October 28, 2004Applicant: Ajinomoto Co., Inc.Inventors: Kazuhiro Hasegawa, Toshiya Tanabe, Keita Minami
-
Patent number: 6797699Abstract: Compounds of formula (I) wherein: Q represents an amidino group, a cyano group or a group of formula XYN—, (where X and Y are hydrogen or various groups); Ra represents alkylene; Rb and Rc each represents alkylene, the total number of carbon atoms in said straight chains of Rb and Rc being 7); R2 and R3 each represents hydrogen, or a group of formula R, RCO—, ROCO—, or RNHCO—, where R represents alkyl or aryl; the chiral carbon atom indicated by the asterisk is in the L configuration; Z is an aromatic amino acid residue; n is 0 or 1; R1 represents hydrogen, alkyl or aryl; and W represents hydrogen, alkyl or aryl; and pharmaceutically acceptable salts thereof have the ability to protect against the neuronal damage which may be caused by an ischemic event.Type: GrantFiled: October 2, 2000Date of Patent: September 28, 2004Assignee: University of SouthamptonInventors: Lars Eric Sundstrom, Fausto Iannotti, Mark Bradley, Ashley Ker Pringle